Hjem › Brystkreft › District of Columbia
Kliniske studier for Brystkreft i District of Columbia
28 studier for Brystkreft søker deltakere på steder i District of Columbia.
Byer i District of Columbia
Offisiell studietekst (engelsk)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Georgetown University Medical Center, Washington D.C.
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06982521Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Georgetown University Lombardi Cancer Center, Washington D.C.
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Older Breast Cancer Patients: Risk for Cognitive Decline
- Georgetown University, Washington D.C.
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 60 til 105 · Kvinner · Oppdatert 28. sep. 2026 · NCT03451383ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- The George Washington Medical facility Associates, Washington D.C.
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07007559A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- MedStar Washington Hospital Center, Washington D.C.
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07174336A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Georgetown Uni Hospital, Washington D.C.
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05894239Identifying Patterns in the Breath of Individuals With Breast Cancer
- GW Comprehensive Breast Center, Washington D.C.
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 74 · Kvinner · Oppdatert 18. sep. 2026 · NCT06512350A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Georgetown University Medical Center, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06492616A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center, Washington D.C.
RekruttererFase 1
Alder 18 til 55 · Kvinner · Oppdatert 9. sep. 2026 · NCT07310420Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Georgetown University, Washington D.C.
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT05315700Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- og 2 flere
RekruttererFase 3
Alder 18 til 60 · Kvinner · Oppdatert 2. sep. 2026 · NCT05879926TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Georgetown University Medical Center, Washington D.C.
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2026 · NCT06533826Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
- Sibley Memorial Hospital, Washington D.C.
Rekrutterer
Alder 18 og eldre · Kvinner · Oppdatert 21. aug. 2026 · NCT06536881Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Sibley Memorial Hospital, Washington D.C.
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06500481Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital, Washington D.C.
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
RekruttererFase 3
Alder 18 til 50 · Alle kjønn · Oppdatert 4. aug. 2026 · NCT06748222I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Georgetown University Medical Center, Washington D.C.
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT01042379A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- MedStar Washington Hospital Center, Washington D.C.
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT07062965De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- George Washington University Medical Center, Washington D.C.
RekruttererFase 3
Alder 50 til 70 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT04852887Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Cancer Support Community Research & Training Institute, Washington D.C.
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 23. apr. 2026 · NCT02333604Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
- Georgetown University, Washington D.C.
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. apr. 2026 · NCT04841148Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
- George Washington-Medical Faculty Associates, Washington D.C.
RekruttererFase 2
Alder 21 og eldre · Alle kjønn · Oppdatert 3. mar. 2026 · NCT06806930The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
- Sibley Memorial Hospital, Washington D.C.
Rekrutterer
Alder 18 og eldre · Kvinner · Oppdatert 23. feb. 2026 · NCT05780814Study in Patients With Breast Cancer Leptomeningeal Metastasis
- Sibley Memorial Hospital, Washington D.C.
RekruttererObservasjonsstudie
18 Weeks · Alle kjønn · Oppdatert 28. nov. 2025 · NCT06638294The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
- Georgetown University, Washington D.C.
Rekrutterer
Alder 18 til 74 · Kvinner · Oppdatert 30. sep. 2025 · NCT06892275CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Kvinner · Oppdatert 28. aug. 2025 · NCT05130606CtDNA Based MRD Testing for NAC Monitoring in TNBC
- George Washington University, Washington D.C.
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 7. jan. 2025 · NCT06230185Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.